PolyNovo Limited

ASX:PNV Stock Report

Market Cap: AU$1.8b

PolyNovo Valuation

Is PNV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PNV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PNV (A$2.58) is trading below our estimate of fair value (A$3.06)

Significantly Below Fair Value: PNV is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PNV?

Other financial metrics that can be useful for relative valuation.

PNV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue16.7x
Enterprise Value/EBITDA653.7x
PEG Ratio8.9x

Price to Sales Ratio vs Peers

How does PNV's PS Ratio compare to its peers?

The above table shows the PS ratio for PNV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
NAN Nanosonics
6.3x8.7%AU$1.1b
ANN Ansell
1.8x6.7%AU$4.3b
NXS Next Science
1.7x29.3%AU$58.4m
SDI SDI
1x5.4%AU$114.7m
PNV PolyNovo
17.3x17.5%AU$1.8b

Price-To-Sales vs Peers: PNV is expensive based on its Price-To-Sales Ratio (17.3x) compared to the peer average (2.7x).

Price to Earnings Ratio vs Industry

How does PNV's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: PNV is expensive based on its Price-To-Sales Ratio (17.3x) compared to the Australian Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is PNV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PNV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.3x
Fair PS Ratio10.3x

Price-To-Sales vs Fair Ratio: PNV is expensive based on its Price-To-Sales Ratio (17.3x) compared to the estimated Fair Price-To-Sales Ratio (10.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PNV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$2.58
AU$2.61
+1.0%
23.6%AU$3.00AU$1.05n/a8
Sep ’25AU$2.34
AU$2.61
+11.4%
23.6%AU$3.00AU$1.05n/a8
Aug ’25AU$2.72
AU$2.37
-13.0%
23.2%AU$2.80AU$1.05n/a8
Jul ’25AU$2.33
AU$2.14
-8.1%
23.6%AU$2.75AU$1.00n/a8
Jun ’25AU$2.25
AU$2.11
-6.1%
22.8%AU$2.75AU$1.00n/a8
May ’25AU$2.01
AU$2.11
+5.1%
22.8%AU$2.75AU$1.00n/a8
Apr ’25AU$2.19
AU$2.11
-3.5%
22.8%AU$2.75AU$1.00n/a8
Mar ’25AU$2.20
AU$2.11
-3.9%
22.8%AU$2.75AU$1.00n/a8
Feb ’25AU$1.87
AU$1.95
+4.2%
26.1%AU$2.90AU$1.00n/a8
Jan ’25AU$1.66
AU$1.81
+9.6%
29.4%AU$2.70AU$1.00n/a8
Dec ’24AU$1.39
AU$1.88
+35.0%
30.0%AU$2.70AU$1.00n/a8
Nov ’24AU$1.20
AU$1.88
+56.4%
30.0%AU$2.70AU$1.00n/a8
Oct ’24AU$1.31
AU$1.88
+43.8%
30.0%AU$2.70AU$1.00n/a8
Sep ’24AU$1.41
AU$2.11
+49.8%
29.0%AU$2.90AU$1.08AU$2.346
Aug ’24AU$1.58
AU$2.25
+42.8%
31.9%AU$2.90AU$0.90AU$2.726
Jul ’24AU$1.55
AU$2.25
+45.6%
31.9%AU$2.90AU$0.90AU$2.336
Jun ’24AU$1.47
AU$2.25
+53.5%
31.9%AU$2.90AU$0.90AU$2.256
May ’24AU$1.63
AU$2.53
+54.9%
14.4%AU$2.90AU$1.90AU$2.016
Apr ’24AU$1.79
AU$2.53
+41.1%
14.4%AU$2.90AU$1.90AU$2.196
Mar ’24AU$2.33
AU$2.53
+8.4%
14.4%AU$2.90AU$1.90AU$2.206
Feb ’24AU$2.49
AU$2.09
-16.1%
25.9%AU$2.85AU$1.20AU$1.875
Jan ’24AU$2.02
AU$1.98
-2.0%
21.0%AU$2.30AU$1.20AU$1.665
Dec ’23AU$2.03
AU$1.90
-6.4%
22.6%AU$2.30AU$1.20AU$1.394
Nov ’23AU$2.04
AU$1.70
-16.7%
17.0%AU$1.90AU$1.20AU$1.206
Oct ’23AU$1.30
AU$1.69
+29.7%
18.7%AU$1.90AU$1.11AU$1.316
Sep ’23AU$1.34
AU$1.68
+25.6%
18.4%AU$1.90AU$1.11AU$1.416

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y